Results 71 to 80 of about 634,895 (315)
Mathematical analysis of a two-strain disease model with amplification [PDF]
arXiv, 2019 We investigate a two-strain disease model with amplification to simulate the prevalence of drug-susceptible (s) and drug-resistant (m) disease strains. We model the emergence of drug resistance as a consequence of inadequate treatment, i.e. amplification.
arxiv
Molecular Oncology, EarlyView.The authors analyzed the spatial distributions of gene and metabolite profiles in cervical cancer through spatial transcriptomic and spatially resolved metabolomic techniques. Pivotal genes and metabolites within these cases were then identified and validated.
Lixiu Xu +3 more
wiley +1 more source
Drug Design, Development and Therapy, 2020 Jingsheng Xia,1 Peng Chen2 1Department of Pharmacy, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan, Hubei 430060, People’s Republic of China; 2Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060 ...
Xia J, Chen P
doaj
3D Printed Calcium Phosphate Cement (CPC) Scaffolds for Anti-Cancer Drug Delivery
Pharmaceutics, 2020 One of the main applications of bone graft materials is filling the gap after the surgical removal of bone cancer or tumors. Insufficient healing commonly leads to non-union fracture which could lead to cancer resurgence or infection.
Yan Wu +5 more
doaj +1 more source
A hybrid quantum-classical fusion neural network to improve protein-ligand binding affinity predictions for drug discovery [PDF]
arXiv, 2023 The field of drug discovery hinges on the accurate prediction of binding affinity between prospective drug molecules and target proteins, especially when such proteins directly influence disease progression. However, estimating binding affinity demands significant financial and computational resources.
arxiv
Molecular Oncology, EarlyView.The authors applied joint/mixed models that predict mortality of trifluridine/tipiracil‐treated metastatic colorectal cancer patients based on circulating tumor DNA (ctDNA) trajectories. Patients at high risk of death could be spared aggressive therapy with the prospect of a higher quality of life in their remaining lifetime, whereas patients with a ...
Matthias Unseld +7 more
wiley +1 more source
Crosstalk between gut microbiota and tumor: tumors could cause gut dysbiosis and metabolic imbalance
Molecular Oncology, EarlyView.In this research, we analyzed the relationship between gut microbiota and tumor. We discovered that both subcutaneous and metastatic tumors would alter the composition and metabolic function of gut microbiota. Meanwhile, fecal microbiota transplantation also indicated the anti‐tumor role of the gut microbiota, revealing the crosstalk between tumor and ...
Siyuan Zhang +8 more
wiley +1 more source
Revista de Ciências Farmacêuticas Básica e Aplicada, 2021 Objective: The aim of this study was to highlight and sediment the necessary steps to be followed while conducting forced degradation studies to identify degradation products and to describe the Brazilian and international regulations associated with ...
Fernanda Fernandes Farias +4 more
doaj
Molecular Oncology, EarlyView.The authors conducted a retrospective study of 94 patients with advanced cancer who underwent next‐generation sequencing (NGS) gene panel analysis and received targeted treatments when applicable. Results further support evidence indicating that molecular profiling provides clinical benefit.
Michaël Dang +3 more
wiley +1 more source
KMT2A degradation is observed in decitabine‐responsive acute lymphoblastic leukemia cells
Molecular Oncology, EarlyView.We demonstrate that decitabine (DEC) not only degrades the DNA methyltransferase DNMT1 but also the leukemic driver lysine methyltransferase KMT2A likely due to structural similarity of the DNA‐binding CXXC domains. DEC influences KMT2A downstream processes and synergizes with menin inhibitor revumenib (REV) to decrease leukemic cell proliferation, and
Luisa Brock +10 more
wiley +1 more source